Form 4: Kineta Director Exercises Options and Acquires Shares Following TuHURA Biosciences Merger Approval

Kineta, Inc. Director Kimberlee C. Drapkin reported the exercise of stock options and acquisition of common stock, alongside a tax-related disposition, following the approval of the merger agreement with TuHURA Biosciences, Inc.

Summary

• Kimberlee C. Drapkin, a Director of Kineta, Inc. (KANT), reported changes in her beneficial ownership of the company's common stock.
• On June 23, 2025, Ms. Drapkin exercised stock options to acquire 12,500 shares of common stock at an exercise price of $0.611 per share.
• Concurrently on June 23, 2025, 4,706 shares were disposed of at a price of $0.26 per share to cover tax withholding obligations related to the option exercise.
• On June 25, 2025, Ms. Drapkin acquired an additional 6,000 shares of common stock at a price of $0.
• The options granted under the 2022 Equity Incentive Plan became fully vested on June 23, 2025, pursuant to the Optionholder Treatment Agreement and the Agreement and Plan of Merger with TuHURA Biosciences, Inc., which was approved by Kineta's stockholders on June 23, 2025.
• Following these transactions, Ms. Drapkin beneficially owns 13,794 shares of Kineta Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The exercise of options and acquisition of shares by a director generally signals confidence. While there was a tax-related disposition, it's a standard practice. The underlying event (merger approval) is a significant corporate milestone.

Positives

• A director exercised stock options, indicating confidence in the company's future.
• The full vesting of options for the reporting person on June 23, 2025, aligns with the terms of the merger agreement, signaling progress in the corporate transaction.

Negatives

• A portion of the acquired shares (4,706 shares) was disposed of to cover tax withholding obligations, which is a common practice but reduces the net shares held.

Future Outlook

The document indicates the approval of the merger agreement with TuHURA Biosciences, Inc., suggesting the transaction is progressing towards completion. No specific financial guidance or forward-looking statements beyond the merger's progression are provided.

Industry Context

This Form 4 filing reflects a routine insider transaction following a significant corporate event, specifically a merger approval, which is common in the biotechnology and pharmaceutical sectors as companies consolidate or restructure. The vesting of options tied to such events is a standard practice to align executive incentives with shareholder interests during M&A activities.

Corporate Governance

Related Party Transactions

• The exercise of stock options and acquisition/disposition of shares by a director (Kimberlee C. Drapkin) are considered related party transactions, as they involve a key management personnel and the company.

Stakeholder Impact

• Shareholders: The merger approval and subsequent insider transactions provide transparency regarding director ownership changes in the context of a significant corporate restructuring.
• Employees (specifically the Reporting Person): The vesting of options impacts the compensation and equity holdings of the director.

Next Steps

• Completion of the merger between Kineta, Inc. and TuHURA Biosciences, Inc., following stockholder approval.

Key Dates

Keywords

Kineta Inc., KANT, SEC Form 4, Insider Trading, Stock Options, Merger Agreement, TuHURA Biosciences, Director Stock Ownership, Equity Incentive Plan, Beneficial Ownership